Full-Time

Investigator Payments Coordinator

Posted on 5/11/2026

Icon

Icon

10,001+ employees

Global drug and device development services

No salary listed

Chennai, Tamil Nadu, India + 1 more

More locations: Dublin, Ireland

Hybrid

Category
Accounting (1)
Required Skills
Oracle
Excel/Numbers/Sheets
Requirements
  • Good interpersonal skills and relationship management are essential for dealing with people at all levels
  • Strong team player with high self-motivation and positive ‘can-do’ attitude, who can deliver high value output independently and work with team members to ensure high quality results
  • Excellent attention to detail, and a real commitment to delivering high quality outputs
  • Computer-literate with experience in Oracle and Microsoft Excel
  • Advanced communication and organizational and problem-solving skills
  • Knowledge of clinical operations, protocols and site budgets
  • A bachelor’s degree preferred or + 3 years of relevant experience
Responsibilities
  • To support the Investigator Payments team with set up and maintenance of ICON’s investigators payments as appropriate
  • To support team lead and be the main point of contact for issue escalation in the absence of a more senior member of IPG team
  • To positively contribute to the IP group by seeking to continuously improve their job performance and knowledge of IPG systems and processes
  • To support Clinical staff in executing accurate, timely and efficient investigator payments in accordance with investigator contract
  • Prepare communication materials/ payment data for internal/ external clients relating to investigator payments/reporting as appropriate
  • To host training sessions/ meetings relating to IPG processes and procedures
  • To route correspondence appropriately and ensure all queries raised have been assigned to the correct team member in a timely manner
  • To escalate payment issues/delays appropriately
  • To review payments in line with site contracts and visit data to ensure sites are being paid in a timely accurate and efficient manner and escalate delays/ issues appropriately
  • To prepare, host and report on Clinical/IPG study status meetings and contribute to reporting on status of studies in relation to investigator payments
  • To set up, organise and maintain clinical study/ IPG and supporting documentation as appropriate
  • Conduct day to day activities in a professional, service-orientated and client orientated manner
  • Maintain positive, strong working relationships with clients, vendors and staff
  • Work with team lead/supervisor as required to quality check /review work completed by internal IPG staff and other departments
  • Communicate effectively with investigative site personnel and/or ICON or Sponsor Clinical Project Managers, regarding payment inquiries and managing their expectations accordingly
  • Liaise with all other ICON departments such as Clinical, Patient Treatment Services, IT, Finance, legal and contracts to ensure payment queries are speedily resolved
  • To effectively build and maintain a productive working relationship with the Clinical teams and other ancillary department staff to effectively manage their needs and expectations in relation to payments
  • Oversee and be accountable for the quality of the payments in the studies assigned to ensure they are conducted in an effective manner, meeting agreed timelines and expectations and in accordance with IPG KPIs, work product standards and SOPs, appropriate regulations and ICON’s quality standards
  • Generate and validate the export payment files from ICONomics (upload file) to the Accounts Payable department for posting. After payments are complete, ensure payment details are uploaded into ICONomics
  • Perform first level and second level accuracy examination of Payment Due Forms, comparing the paper copies of the forms to the electronic upload file, ensuring proper coding in accordance with standard group procedures
  • Ensure each vendor has been set up in ICON financial systems and that any new information relating to existing vendors is appropriately progressed through to relevant finance staff
  • Be accountable for the quality of how each study assigned is set-up and maintained, ensuring payments are correct and that all work carried out is in accordance with IPG processes and procedures and is audit ready
  • Update IPG systems with any changes from site contracts for assigned studies, as applicable
  • Communicate with assigned Project Managers to establish payment timelines that will allow appropriate processing time for timely payment runs as defined by investigator contract
  • Contribute to writing/updating IPG SOPs/WPs as requested
  • Liaise with the Clinical teams to ensure that all ICONomics data/information is both current and accurate
  • Review all site contracts and accurately set up the proposed payees and budget schedule as governed by the signed Investigator contract
  • Review contracts in coordination with the other members of the set-up team to ensure that the contract specific budget schedule and terms can be facilitated via the IPG system
  • Represent the Investigator Payments Group systems set-up meetings to ensure content of meeting is consistent with capacity and capability of IPG and in line with ICON processes and procedures
  • Accurately record and update all applicable logs and maintain all IPG related files and tracking tools as requested
  • Send meeting requests, book meeting rooms or teleconference facilities for meetings as required
  • Record, prepare and distribute meeting minutes as requested
  • Be familiar with IPG and industry standards, appropriate regulations and relevant IPG and ICON processes and procedures
  • Contribute to process improvement initiatives within IPG and the wider organisation
  • Meet all IPG iLearn/training requirements appropriate to this position
  • Ensure ICON’s reputation for excellence is carried through and maintained throughout all IPG administrative processes and highlight areas for improvement as needed
  • Special Projects/assignments as requested
Desired Qualifications
  • None

Provides consulting, development, and commercialization services for drugs and medical devices through a global network to help clients accelerate development and bring products to market. A global team of experts in 53 countries offers end-to-end support across strategy, development, regulatory, manufacturing, and market access to reduce time to market, lower costs, and improve quality. The company differentiates itself with its large global presence, clear focus on speed and cost, and extensive experience across therapeutic areas. Its goal is to help clients accelerate the development of life-saving drugs and devices by delivering high-quality information, solutions, and performance.

Company Size

10,001+

Company Stage

IPO

Headquarters

Ireland

Founded

1990

Simplify Jobs

Simplify's Take

What believers are saying

  • Advarra integration reduces administrative friction and accelerates study startups.
  • Oncology expansion adds 14 oncologists to boost patient recruitment.
  • Jefferies upgrades ICON to Buy with $135 target post-selloff.

What critics are saying

  • Audit probe reveals $160M revenue overstatements, delaying Q4 2025 results to April 30.
  • Holzer & Holzer, Levi & Korsinsky lawsuits erode investor confidence immediately.
  • IQVIA captures 20% more biotech trials via superior AI site selection.

What makes Icon unique

  • ICON partners with Advarra on March 24, 2026, for connected site network using Braid AI.
  • Accellacare expands oncology via Brian Moran Cancer Institute partnership in Illinois.
  • Deepali Suri leads biotech division since September 2025 with AI-enabled solutions.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Icon who can refer or advise you

Benefits

Health Insurance

Paid Vacation

401(k) Retirement Plan

Mental Health Support

Life Insurance

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

-13%

1 year growth

-13%

2 year growth

-13%
Resonate Group
Mar 24th, 2026
Icon, Advarra partnership aims to optimize trials, expand access.

Icon, Advarra partnership aims to optimize trials, expand access. * March 24, 2026 Clinical research organization Icon has entered into a partnership with research technology company Advarra to launch a network of connected sites for clinical trials. Fields (*) Mark are Required

Business Wire
Mar 24th, 2026
ICON and Advarra launch connected site network to streamline clinical trials

ICON plc and Advarra have partnered to introduce a "research-ready" connected site network model for clinical trials. The partnership integrates ICON's global clinical trial solutions with Advarra's site systems, already used by over 50,000 investigators worldwide, including researchers at 90 of the top 125 academic medical centres. The collaboration will create a shared operating environment that reduces administrative burden, accelerates study startup and increases clinical trial participation. Advarra will provide operational intelligence through its Braid AI platform to help ICON optimise protocol design and improve site identification. The companies plan to equip emerging and research-naïve sites with Advarra's technology, enabling broader geographic diversity in clinical trials. Last year, Advarra's systems managed over $4 billion in trial invoice value and three million patient visits.

Contract Pharma
Mar 24th, 2026
ICON, Advarra partner on connected site network model.

ICON, Advarra partner on connected site network model. Partnership will integrate ICON's global clinical trial services with Advarra's site CTMSs, eISF, and eSource systems. March 24, 2026 Managing Editor, Contract Pharma ICON plc, a clinical research organization, and Advarra, a provider of connected, intelligence-powered research technology, have entered a partnership agreement to introduce a new 'research-ready,' connected site network model for clinical trials. The partnership will integrate ICON's global clinical trial services with Advarra's site CTMSs, eISF, and eSource systems. This approach leverages Advarra's Study Collaboration as the connector to ICON's technology to create a shared operating environment for ICON studies that aims to reduce administrative friction, accelerate study startup, and increase clinical trial participation. Advarra will also provide ICON with operational intelligence through Study Collaboration, built on Braid, Advarra's data and AI platform that draws on operational insights from its IRB and clinical trial systems. The intelligence will help ICON further optimize protocol design, improve forecasting and study planning, and strengthen research site identification and feasibility decisions. With a clearer understanding of research site capacity, workflow realities, and historical operational patterns, the goal is to allow for studies to be planned more realistically and executed with fewer downstream adjustments. In addition, ICON and Advarra will work together to expand access to clinical trials by enabling more research sites worldwide to support today's increasingly complex study requirements. The companies plan to equip emerging and research-naïve sites, along with select sites working with ICON, with Advarra's site technology, helping standardize operations and reduce manual processes. "Research sites should not have to adapt their operations for every new study or sponsor, and ICON and Advarra are focused on meeting sites where they are, prioritising their needs and removing that burden through this partnership," said Barry Balfe, CEO of ICON plc. "By aligning ICON's workflows with the systems sites already use every day, we're advancing a more practical and scalable way to run trials that reduces administrative burden on sites." "Sites do their best work when they can stay focused on patients and study delivery, not on managing fragmented processes," said Gadi Saarony, CEO of Advarra. "By integrating ICON's technology with the Advarra systems sites already use, this partnership allows sites to work in their native systems, reducing rework, improving consistency, and streamlining workflows. For sponsors, it means trials can move forward with greater speed and confidence, helping promising therapies move through development more efficiently and reach patients sooner."

Yahoo Finance
Mar 5th, 2026
Jefferies upgrades ICON to buy as accounting probe selloff deemed overdone

Jefferies has upgraded ICON Public Limited Company to Buy from Hold, lowering its price target to $135 from $175. Analyst David Windley cited the stock's valuation as "hard to ignore", noting that whilst AI could compress labour-intensive businesses, the market may underestimate regulatory hurdles to rapid tech adoption. The upgrade follows TD Cowen's recent move to Buy from Hold with a $120 price target, describing the risk-reward as "compelling" after a 33% selloff tied to an internal accounting investigation. ICON disclosed in February that preliminary findings indicate revenue for 2023 and 2024 may have been overstated by less than 2% each year. The company withdrew its 2025 guidance and plans to release fourth-quarter results by 30th April.

PR Newswire
Feb 18th, 2026
ICON plc shares drop 40% after internal probe uncovers $160M annual revenue overstatement

ICON plc, one of the world's largest contract research organisations, is facing investigation after disclosing on 12 February that an internal accounting probe uncovered preliminary evidence of revenue overstatements by up to 2% in fiscal years 2023 and 2024. The disclosure prompted the company to delay releasing its fourth-quarter and full-year 2025 financial results. With reported annual revenue exceeding $8 billion, a 2% overstatement would represent approximately $160 million per year. Following the announcement, ICON shares declined roughly 40%, erasing billions in market capitalisation. Law firm Levi & Korsinsky is investigating the Dublin-based company, which provides outsourced drug development and clinical trial management services. During 2025, ICON repurchased $750 million of its own shares and authorised an additional $1 billion buyback programme.

INACTIVE